Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2015 1
2017 2
2018 1
2019 1
2020 2
2021 1
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.
Takase S, Hiroyama T, Shirai F, Maemoto Y, Nakata A, Arata M, Matsuoka S, Sonoda T, Niwa H, Sato S, Umehara T, Shirouzu M, Nishigaya Y, Sumiya T, Hashimoto N, Namie R, Usui M, Ohishi T, Ohba SI, Kawada M, Hayashi Y, Harada H, Yamaguchi T, Shinkai Y, Nakamura Y, Yoshida M, Ito A. Takase S, et al. Among authors: shirai f. Nat Commun. 2023 Jan 12;14(1):23. doi: 10.1038/s41467-022-35404-0. Nat Commun. 2023. PMID: 36635268 Free PMC article.
Novel tankyrase inhibitors suppress TDP-43 aggregate formation.
Tanji K, Mori F, Shirai F, Fukami T, Seimiya H, Utsumi J, Kakita A, Wakabayashi K. Tanji K, et al. Among authors: shirai f. Biochem Biophys Res Commun. 2021 Jan 22;537:85-92. doi: 10.1016/j.bbrc.2020.12.037. Epub 2020 Dec 30. Biochem Biophys Res Commun. 2021. PMID: 33387887
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H. Chen M, et al. Among authors: shirai f. Br J Cancer. 2024 Jan;130(1):151-162. doi: 10.1038/s41416-023-02484-8. Epub 2023 Nov 15. Br J Cancer. 2024. PMID: 37968472
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H. Shirai F, et al. J Med Chem. 2019 Apr 11;62(7):3407-3427. doi: 10.1021/acs.jmedchem.8b01888. Epub 2019 Apr 1. J Med Chem. 2019. PMID: 30883102
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H. Shirai F, et al. J Med Chem. 2020 Apr 23;63(8):4183-4204. doi: 10.1021/acs.jmedchem.0c00045. Epub 2020 Apr 1. J Med Chem. 2020. PMID: 32202790
14 results